Comparative Pharmacology
Head-to-head clinical analysis: PHENETRON versus PROMETHAZINE W CODEINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENETRON versus PROMETHAZINE W CODEINE.
PHENETRON vs PROMETHAZINE W/ CODEINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenetron is an antihistamine that competes with histamine for H1-receptor sites, blocking histamine-mediated effects in the respiratory tract, vascular system, and gastrointestinal tract. It also exhibits anticholinergic and sedative properties.
Codeine is a prodrug converted to morphine, a mu-opioid receptor agonist, which inhibits nociceptive transmission; promethazine is a phenothiazine derivative with H1-receptor antagonism, anticholinergic, and antiemetic effects.
Adults: 50 mg intramuscularly every 6 hours as needed.
10 mL (1 mg codeine, 6.25 mg promethazine per 5 mL) orally every 4-6 hours as needed for cough. Maximum: 60 mL per day. Do not exceed 5 days.
None Documented
None Documented
Terminal half-life 12–15 hours; clinically, steady-state achieved in ~3 days
Promethazine: 10-19 hours (terminal). Codeine: 2.5-3.5 hours (terminal); prolonged in renal impairment.
Renal: ~70% unchanged; Biliary/Fecal: ~15% as metabolites; 15% unidentified
Promethazine: renal (70% as metabolites, <1% unchanged), fecal (20-30%). Codeine: renal (90%, of which 5-10% unchanged, rest as metabolites), fecal (minor).
Category C
Category A/B
Antihistamine
Antihistamine / Antiemetic